Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2017, Article ID 3835825, 5 pages
https://doi.org/10.1155/2017/3835825
Case Report

Usefulness of Endoscopic Managements in Patients with Ceftriaxone-Induced Pseudolithiasis Causing Biliary Obstruction

1Department of Internal Medicine, Munakata Medical Association Hospital, Fukuoka, Japan
2Department of Surgery, Munakata Medical Association Hospital, Fukuoka, Japan
3Department of Nephrology, Munakata Medical Association Hospital, Fukuoka, Japan

Correspondence should be addressed to Yasuhiro Doi; pj.oc.oohay@dleiforihusayiod

Received 10 July 2017; Accepted 25 September 2017; Published 2 November 2017

Academic Editor: William B. Silverman

Copyright © 2017 Yasuhiro Doi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Richards, R. C. Heel, R. N. Brogden, T. M. Speight, and G. S. Avery, “Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use,” Drugs, vol. 27, no. 6, pp. 469–527, 1984. View at Publisher · View at Google Scholar · View at Scopus
  2. U. B. Schaad, H. Tschäppeler, and M. J. Lentze, “Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy,” Pediatric Infectious Disease, vol. 5, no. 6, pp. 708–710, 1986. View at Publisher · View at Google Scholar
  3. R. H. Meyboom, H. Kuiper, and A. Jansen, “Ceftriaxone and reversible cholelithiasis,” BMJ, vol. 297, no. 6652, p. 858, 1988. View at Publisher · View at Google Scholar
  4. C. Pigrau, A. Pahissa, S. Gropper, D. Sureda, and J. M. Martinez Vazquez, “Ceftriaxone-associated biliary pseudolithiasis in adults,” Lancet, vol. 334, no. 8655, p. 165, 1989. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Brogard, J. F. Blickle, F. Jehl, J. P. Arnaud, D. Paris-Bockel, and H. Monteil, “High biliary elimination of ceftriaxone in man,” International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 26, no. 4, pp. 167–172, 1988. View at Google Scholar
  6. H. Z. Park, S. P. Lee, and A. L. Schy, “Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate,” Gastroenterology, vol. 100, no. 6, pp. 1665–1670, 1991. View at Publisher · View at Google Scholar
  7. A. J. Lopez, P. O’Keefe, M. Morrissey, and J. Pickleman, “Ceftriaxone-induced cholelithiasis,” Annals of Internal Medicine, vol. 115, no. 9, pp. 712–714, 1991. View at Publisher · View at Google Scholar
  8. M. L. Shiffman, F. B. Keith, and E. W. Moore, “Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility,” Gastroenterology, vol. 99, no. 6, pp. 1772–1778, 1990. View at Publisher · View at Google Scholar
  9. U. B. Schaad, J. Wedgwood-Krucko, and H. Tschaeppeler, “Reversible ceftriaxone-associated biliary pseudolithiasis in children,” Lancet, vol. 332, no. 8625, pp. 1411–1413, 1988. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Ozturk, M. Kaya, D. Zeyrek, E. Ozturk, N. Kat, and S. Z. Ziylan, “Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children,” Acta Radiologica, vol. 46, no. 1, pp. 112–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Biner, N. Öner, C. Çeltik et al., “Ceftriaxone-associated biliary pseudolithiasis in children,” Journal of Clinical Ultrasound, vol. 34, no. 5, pp. 217–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Soysal, K. Eraşov, I. Akpinar, and M. Bakir, “Biliary precipitation during ceftriaxone therapy: frequency and risk factors,” Turkish Journal of Pediatrics, vol. 49, no. 4, pp. 404–407, 2007. View at Google Scholar
  13. A. Palanduz, I. Yalçin, E. Tonguç et al., “Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children,” Journal of Clinical Ultrasound, vol. 28, no. 4, pp. 166–168, 2000. View at Publisher · View at Google Scholar
  14. S. Murata, T. Aomatsu, A. Yoden, and H. Tamai, “Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis,” Pediatrics International, vol. 57, no. 5, pp. 942–946, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. K. L. Heim-Duthoy, E. M. Caperton, R. Pollock, G. R. Matzke, D. Enthoven, and P. K. Peterson, “Apparent biliary pseudolithiasis during ceftriaxone therapy,” Antimicrobial Agents and Chemotherapy, vol. 34, no. 6, pp. 1146–1149, 1990. View at Publisher · View at Google Scholar
  16. K. Dohmen, A. Yamamoto, H. Tanaka, M. Haruno, and S. Shimoda, “An elderly case of ceftriaxone-associated pseudolithiasis that developed during therapy for acute pneumonia,” Kanzo, vol. 57, no. 2, pp. 106–112, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. F. M. Robertson, T. M. Crombleholme, S. E. Barlow, M. Verhave, and D. Brown, “Ceftriaxone choledocholithiasis,” Pediatrics, vol. 98, no. 1, pp. 133–135, 1996. View at Google Scholar
  18. M. C. Maranan, S. I. Gerber, and G. G. Miller, “Gallstone pancreatitis caused by ceftriaxone,” Pediatric Infectious Disease Journal, vol. 17, no. 7, pp. 662-663, 1998. View at Google Scholar
  19. G. Famularo, S. Polchi, and C. De Simone, “Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication,” Annali Italiani di Medicina Interna, vol. 14, no. 3, pp. 202–204, 1999. View at Google Scholar
  20. E. Lebovics, M. S. Halata, J. A. Rosario, J. Lantin, S. M. Schwarz, and W. S. Rosenthal, “Endoscopic management of ceftriaxone pseudolithiasis involving the common bile duct and gallbladder,” Gastrointestinal Endoscopy, vol. 40, no. 2, pp. 246–248, 1994. View at Publisher · View at Google Scholar
  21. C. Blais and R. Duperval, “Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy,” Pediatric Radiology, vol. 24, no. 3, pp. 218-219, 1994. View at Publisher · View at Google Scholar · View at Scopus